Pegfilgrastim-Bmez(Clariant Ag)

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering. Understanding the rapidly advancing sector of injectable hematology growth factors is crucial for stakeholders in the healthcare industry. The latest comprehensive report evaluates the intersection of technology, products, and key players that are shaping this dynamic segment, with particular emphasis on devices designed for patient self-administration. The study presents an in-depth examination of the evolving therapeutic care landscape, highlighting significant developments in the treatment of conditions such as anemia, neutropenia, and thrombocytopenia. It analyzes the shift from traditional vials to prefilled injection devices, a trend that is likely to gain momentum over the following five years, emphasizing the market forces driving this change. Key Highlights from the Report: An in-depth analysis of device strategies and product development factors influencing the injectable hematology growth factors delivery systems. Insight into market dynamics and demographics, underpinning industry growth. An evaluation of therapeutic demand drivers across pivotal segments in healthcare. Comprehensive market data and forecast trends to inform strategic decisions. Profiles of sector participants including business strategies and corporate associations. An assessment of how alliances and partnerships affect the commercialization of drug products. Insights into the economic, technological, and regulatory factors impacting the market. Healthcare administrators, investors, and other stakeholders will benefit from this study's findings that not only chart current market conditions but also project future industry directions. It serves as a critical resource for decision-makers aiming to understand and capitalize on the opportunities presented within this segment. The report's findings are pivotal for a broad spectrum of healthcare professionals, including pharmaceutical decision-makers, device developers, healthcare marketers, and supply chain entities. It is particularly geared towards empowering chronically ill patients and enhancing safety protocols through revolutionary drug delivery methods. Stakeholders are poised to gain substantial insights into the strategies propelling the adoption of injectable hematologic treatments, facilitating informed decisions that align with the compelling trends of self-administered therapeutic care. Discover the Future of Injectable Hematology Treatments As the healthcare industry continues its inexorable march towards more patient-centric and self-managed treatment options, understanding the nuances and intricacies of injectable hematology growth factor treatments becomes ever more critical. The recent report provides these vital insights, demarking a clear view of the path forward. Stay informed on the latest in healthcare advancements and market opportunities. For further information and to explore the depth of this report, interested parties are encouraged to delve into the comprehensive analysis that awaits them. Key Topics Covered: Hematology Market Dynamics Competitive Factors Proliferation of Biological Drugs Product Manufacturers Hematology Growth Factors Devices for Administering Injectable Growth Factors Device Selection - Stability and Material Issues Competitive Landscape Prefilled Syringes Pen Injectors Dual Chamber Pens Emerging Devices Injectable Hematology Growth Factors - Product Assessment Abseamed Accofil Aranesp Binocrit Biograstim Biopoin Epoetin Alfa Hexal Eporatio Filgrastim Hexal Fulphila Granix Grastofil Mircera NeoRecormon Neulasta Neupogen Nivestim Ratiograstim Retacrit Rolvedon Silapo Tevagrastim Udenyca (Coherus BioSciences) Zarzio Ziextenzo Market Assessment Anemia Hematopoietic Stem Cell Transplant Advanced Kidney Disease Neutropenia Predonation of Autologous Blood Company Profiles Companies Mentioned AbZ-Pharma Accord Healthcare Amgen Genentech Hexal AG Medice Arzneimittel Mylan International Novartis Pfizer Ratiopharm Rentscler Biotechnologie Roche Sandoz Stada Arzneimittel AG Teva Pharmaceuticals For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

On January 22, Sandoz announced that it acquired the ranibizumab biosimilar Cimerli® from Coherus Biosciences for upwards of $190 million. First approved on August 2, 2022, Cimerli was performing well. According to its manufacturing partner, Formycon AG, the product had grabbed 38% of the ranibizumab marketshare (based on IQVIA data), with $125 million in 2023 sales and trending upward for 2024. So why sell? And why the seemingly low price? A couple of factors apparently played a role, based on Coherus CEO Dennis Lanfear’s comments on a webcast. One strong reason for the sale is to provide Coherus cash to pay down its loan debt, said Mr. Lanfear. The Cimerli transaction includes an upfront payment by Sandoz of $170 million in cash and an additional $20 million payment for existing Cimerli doses. The cash may also be needed to fund continuing operations. Despite the strong start in sales, he noted that the company pays a large royalty on Cimerli sales, “which impacts the profit margin significantly. This was the least profitable of their products,” Mr. Lanfear reported. Sales are expected to increase; we recently reported that CVS Health removed Eylea® and Lucentis® from its formulary, leaving Cimerli and Byooviz® as the only options for the intravitreal injectables. Most recently, Coherus received FDA approval for its Udenyca® on-body injector device. This delivery system will compete directly with Neulasta® OnPro® for the dominant pegfilgrastim marketshare (about 45% of all pegfilgrastim sales). The company may need additional cash to take advantage of its considerable market opportunity in that sector. According to the latest data from the Samsung Bioepis Biosimilar Trend Report, Coherus’ share of the non-OnPro market was 29% in the third quarter of 2023. The Cimerli transaction includes transfer of Coherus’ ophthalmology sales and select field reimbursement team to Sandoz. Since the company is leaving the ophthalmology field, Mr. Lanfear stated that it is no longer interested in seeking commercialization of its aflibercept biosimilar (FYB203), and the rights to it have been returned to its manufacturing partner. The FDA filing for FYB203 occurred in June 2023, with a decision expected in the early third quarter of this year. On the other hand, Sandoz has its own aflibercept biosimilar candidate, and an FDA filing may be imminent. The Cimerli agreement with Coherus may provide Sandoz a ready-made ophthalmology sales infrastructure that could be the basis for the marketing of its aflibercept biosimilar as well. Mr. Lanfear hinted that Coherus may not be done selling biosimilar assets. He stated that both ranibizumab and adalimumab biosimilars are “noncore assets.” The anemic 2023 performance of Yusimry® has mirrored that of its adalimumab competitors: At 0.3% marketshare, Coherus may seek a buyer for this product as well, as it narrows its focus to the oncology sector. It will likely keep Udenyca, because of its place in the oncology portfolio. News of the Cimerli sale does confirm that Coherus will not be seeking to bring any new biosimilars to market. Once hailed as a “pure-play” biosimilar manufacturer, it is now evolving into a standard biotech company. Stay tuned for news of similar developments